Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2023 10:14 ET | Source: Booster

Booster Is On Mission to Raise $1 Billion For K-12 Schools by 2026

ATLANTA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Booster, the country’s leading fundraising partner for K-12 schools, released its annual Impact Report, announcing the addition of $125 million raised for...
June 21, 2023 08:17 ET | Source: Booster

BOOSTER EXPANDS PREMIER FUNDRAISING SOLUTIONS, LAUNCHES HIGH SCHOOL FUNDRAISING SERVICES FOR SPORTS AND GROUPS IN 2023-2024 SCHOOL YEAR

ATLANTA, June 21, 2023 (GLOBE NEWSWIRE) -- Booster, the premier partner for K-12 schools in need of raising critical funds with proven, stress-free fundraising solutions is propelling growth plans...
June 09, 2023 09:12 ET | Source: Booster

Booster Collaborates with GoNoodle To Extend Social Emotional Learning In Schools Across The Country

ATLANTA, June 09, 2023 (GLOBE NEWSWIRE) -- School fundraising experts at Booster are partnering with the nationally-recognized team at GoNoodle to introduce its new social emotional learning (SEL)...
March 07, 2023 08:30 ET | Source: Dyadic International, Inc.

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 ...
November 10, 2022 09:45 ET | Source: BioNTech SE

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für Auffrischungsimpfung mit an Omikron BA.4/BA.5 angepasstem bivalenten COVID-19-Impfstoff für Kinder im Alter von 5 bis 11 Jahren in der Europäischen Union

NEW YORK und MAINZ, Deutschland, 10. November 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
November 10, 2022 09:45 ET | Source: BioNTech SE

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

NEW YORK and MAINZ, GERMANY, November 10, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine...
October 13, 2022 06:45 ET | Source: BioNTech SE

Pfizer und BioNTech geben frühe positive Daten aus klinischer Studie mit an Omikron BA.4/BA.5 angepasstem bivalenten Auffrischungsimpfstoff bei Personen ab 18 Jahren bekannt

Seren von Probandinnen und Probanden, die sieben Tage nach Verabreichung einer 30-µg-Auffrischungsimpfung mit dem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff entnommen wurden,...
October 13, 2022 06:45 ET | Source: BioNTech SE

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine showed a substantial increase in the Omicron BA.4/BA.5...
September 26, 2022 06:45 ET | Source: BioNTech SE

Pfizer und BioNTech reichen Antrag auf Notfallzulassung für Auffrischungsimpfung mit einem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff für Kinder von 5 bis 11 Jahren bei der FDA ein

NEW YORK und MAINZ, Deutschland, 26. September 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass sie bei der US-amerikanischen...
September 26, 2022 06:45 ET | Source: BioNTech SE

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

NEW YORK and MAINZ, GERMANY, September 26, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA)...

Next Page keyboard_arrow_right